



Bio Convergence Webinar – Company Information

- **Company Full Name:**

BiomX



- **Website:**

www.biomx.com/

- **Sector/Segment:**

Biotechnology, phage therapy

- **Presenter full name:**

Assaf Oron

- **Presenter title:**

CBO

- **Presenter e-mail:**

assafo@biomx.com

- **Company short description (up to 100 Words)**

BiomX is a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria in multiple indications such as acne, Inflammatory Bowel Disease and cancer. Phage, are viruses that target bacteria and are considered inert to mammalian cells. Phage are designed to target and kill specific bacteria without disrupting other bacteria or the healthy microbiota. BiomX recently announced positive topline data from a phase 1 clinical study of a proprietary topical phage-based product candidate in subjects with acne-prone skin. BiomX is publicly traded on the NYSE and its investors include Johnson & Johnson, Takeda Ventures, OrbiMed and other.

- **Technology description (up to 100 Words)**

BiomX develops both natural and engineered phage cocktails designed to target and destroy bacteria that affect major indications such as IBD and. All of BiomX's phage-based product candidates derive from its proprietary platform, which is first used to discover and validate the link of specific bacterial strains with human diseases, and is then used to develop rationally-designed phage combinations ("cocktails") of phage to target the pathogenic bacteria. The Company's technology is based on research from the laboratories of Profs. Rotem Sorek and Eran Elinav of The Weizmann Institute and Prof. Timothy Lu, of The MIT.



- **Company Full Name:**

MeMed



- **Website:**

www.me-med.com/

- **Sector/Segment:**

Host-response tools for clinical decision-making

- **Presenter full name:**

Dr Tanya Gottlieb

- **Presenter title:**

VP Scientific Affairs

- **Presenter e-mail:**

Tanya.gottlieb@me-med.com

- **Company short description (up to 100 Words)**

Our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society.

- **Technology description (up to 100 Words)**

MeMed BV™ is a pioneering immune-protein signature test, developed and validated over a course of decade-long collaborations with leading academic, governmental and commercial partners. It provides physicians with an indispensable tool to distinguish between bacterial and viral infections with >90% sensitivity and specificity (NPV>98%). Run on the MeMed Key™ platform, the BV™ test provides a result within 15 minutes. BV™ has been validated on >15,000 patients in multinational, double-blind clinical studies (e.g., [Pediatrics](#), [The Lancet ID](#), [PLOS One](#), [BMJ Peds](#)). The BV™ test has a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.



KOREA-ISRAEL
INDUSTRIAL R&D FOUNDATION



רשות החדשנות
Israel Innovation
Authority



Ministry of Economy
and Industry
Foreign Trade Administration





- **Company Full Name:**

Nucleai

- **Website:**

www.nucleaimd.com/

- **Sector/Segment:**

AI

- **Presenter full name:**

Eliron Amir

- **Presenter title:**

COO & Cofounder

- **Presenter e-mail:**


eliron@nucleaimd.com

- **Company short description (up to 100 Words)**

Nucleai is a technology company providing an AI-powered precision oncology platform for research and treatment decisions. The Nucleai platform uses tissue-based data to predict response to Immunotherapy drugs, providing value to pharmaceutical companies at different stages of drug development, from biomarker discovery to clinical trials and companion diagnostics. The company has multiple commercial partnerships, with leading Immunotherapy drug developers and US-based payors.

- **Technology description (up to 100 Words)**

Nucleai's core technology analyzes large and unique datasets of tissue images using computer vision and machine learning methods to model the spatial characteristics of both the tumor and the patient's immune system, creating unique signatures that predict patient response to drugs.





- **Company Full Name:**

ABL Bio



- **Website:**

<http://www.ablbio.com/>

- **Sector/Segment:**

Biotechnology

- **Presenter full name:**

Jaechon Jerry LEE

- **Presenter title:**

Chief Financial Officer

- **Presenter e-mail:**

jerry.lee@ablbio.com

- **Company short description (up to 100 Words)**

ABL Bio Inc., is a South Korean biotechnology company dedicated to developing antibody therapeutics for immuno-oncology and neurodegenerative disease. ABL Bio was founded in 2016 and listed on the Korean stock exchange (KOSDAQ) in 2018. It also raised close to \$200 million USD in less than 3 years, demonstrating a top domestic licensing out record and promising future potential.

- **Technology description (up to 100 Words)**

With its deep expertise in bispecific antibodies and distinguished R&D personnel, ABL Bio has developed its own set of productive BsAb platforms – 'Grabody T,' 'Grabody-I,' and 'Grabody-B.' ABL Bio discovered the first bispecific antibody to undergo clinical trial in South Korea, ABL001. Currently in Phase 1b/2a clinical trial for oncology, ABL001 targets VEGF and is anticipated to be the cornerstone for anti-angiogenic therapy. In the neurodegenerative disorder space, ABL Bio has developed 'Grabody-B' platform designed to maximize blood-brain barrier(BBB) penetrance and therapeutic efficacy. 'Grabody-B' is applicable to various CNS indications, possibly a breakthrough to currently incurable diseases like Parkinson's disease(PD).



- **Company Full Name:**

CHA Biotech Co., LTD



- **Website:**

www.chabio.com/

- **Sector/Segment:**

Biotechnology, Cell Therapeutics

- **Presenter full name:**

Kyoung Eun Kim

- **Presenter title:**

EVP / Head of R&D

- **Presenter e-mail:**

kekim@chamc.co.kr

- **Company short description (up to 100 Words)**

CHA Biotech is a leading company forging a new business paradigm for biotechnology industry. Located in a multidisciplinary research facility where university scientists and hospital physicians can collaborate, it contributes to the advancement of today's cutting-edge stem cell therapy and regenerative medicine technology research.

- **Technology description (up to 100 Words)**

CHA Biotech has been developing next-generation, off-the-shelf stem cell therapies for safer, more accessible, and more affordable treatments. This could be possible through a technique of isolating and culturing stem cells from various sources and cryopreservation that lasts for up to 34 months. A large-scale cell culture process development is underway based on 3D bioreactor system. In addition, cell-free therapeutics development is in progress with exosomes, a paracrine factor known to play a critical role in tissue regeneration.



- **Company Full Name:**

Cytogen, Inc.



- **Website:**

www.cytogenlab.com/

- **Sector/Segment:**

Biotechnology, Liquid Biopsy, Oncology, CTC

- **Presenter full name:**

Hae Ung Lee

- **Presenter title:**

Head, Business Development and Marketing

- **Presenter e-mail:**

hulee@cytogenlab.com

- **Company short description (up to 100 Words)**

CytoGen, Inc. is the global leader in CTC (Circulating Tumor Cell) based liquid biopsy. CytoGen commercialize CTC based liquid biopsy with bio & engineering fusion technology.

- **Technology description (up to 100 Words)**

CytoGen has developed a proprietary CTC isolation and analysis platform, which is fully automated with a high isolation rate of live cells and efficiency. Using the automated platform, CytoGen has analyzed more than 5,000 clinical samples in Korea by collaborating with major Korean Cancer focused Hospitals for the analysis of lung cancer, breast cancer, prostate cancer, Gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, etc.

CytoGen has own fully automated liquid biopsy platform, including Cell isolator, IF Stainer, Cell Image Analyzer.

CytoGen's Liquid Biopsy platform can be utilized throughout the whole process in anticancer drug development.



- **Company Full Name:**

ToolGen, Inc.



- **Website:**

<http://eng.toolgen.com/>

- **Sector/Segment:**

Gene and Cell therapy

- **Presenter full name:**

Seokjoong Kim

- **Presenter title:**

Therapeutic genome editing

- **Presenter e-mail:**

Sj.kim@toolgen.com

- **Company short description (up to 100 Words)**

ToolGen, Inc. is a publicly-traded biotechnology company focused on the development and applications of CRISPR/Cas9 genome editing technology that can be used as essential tools for editing the genetic information in microbial, plant, animal, and human cells. With intellectual properties covering foundational genome editing tools and technologies, our mission is to translate the potential of our innovative platform technology into transformative products for biomedicine and agricultures.

- **Technology description (up to 100 Words)**

CRISPR/Cas9 nucleases are novel, programmable genome engineering tools that were developed from bacterial adaptive immune machinery. With superior efficiency and specificity, CRISPR/Cas9 nucleases enable editing any gene in the living cells in a targeted way. ToolGen is aiming for curing serious human diseases using CRISPR/Cas9 platform technology. Our therapeutic approach focuses on the CRISPR/Cas9-mediated in vivo genome editing therapeutics and ex vivo genome edited cell therapeutics for monogenic rare diseases and other severe health conditions with medical unmet needs.